Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-02-23 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
重大资产重组复牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the resumption of trading after a suspension due to a major asset restructuring. It references previous announcements about the suspension and delay of resumption related to a significant asset reorganization and mentions the approval of related proposals by the board. The content is focused on the status of the stock trading suspension and resumption linked to a major asset restructuring event. This fits the category of a Capital/Financing Update (CAP), as it deals with significant corporate financing and restructuring activities. The document is short and does not contain detailed financial statements or full reports, so it is not an Annual Report or Interim Report. It is not a simple announcement of a report publication, nor is it a regulatory filing or other categories. Therefore, the best classification is Capital/Financing Update (CAP).
2014-02-23 Chinese
北京国枫凯文律师事务所关于公司重大资产重组事项股票交易自查期间内相关人员买卖股票行为的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the stock trading behavior of related personnel during a self-inspection period for a major asset restructuring of a listed company. It references specific dates, stock transactions, and legal compliance checks related to insider trading and stock purchases. The document is titled as a "法律意见书" (legal opinion letter) and is focused on the legality and compliance of stock trading activities during a major asset restructuring. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of a report but a standalone legal opinion on a specific matter related to a major asset restructuring and insider trading. This fits best under the category of Legal Proceedings Report (LTR), as it deals with legal compliance and investigation related to securities law and insider trading during a major corporate event.
2014-02-23 Chinese
华英证券有限责任公司关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion on a major asset restructuring plan involving issuance of shares and cash payment to purchase assets and raise supporting funds. It references compliance with Chinese securities regulations, detailed transaction terms, risk disclosures, and financial assessments. The document is lengthy (15,000 characters) and contains substantive financial and legal analysis related to a major asset restructuring transaction. It is not a simple announcement or certification but a comprehensive advisory report on a capital/financing transaction involving issuance of shares and asset acquisition. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2014-02-23 Chinese
上海执诚生物科技股份有限公司全体股东关于提供信息真实、准确和完整的承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter from all shareholders of Shanghai Zhicheng Biotechnology Co., Ltd. regarding the truthfulness, accuracy, and completeness of information provided in relation to a transaction involving Zhongyuan Xiehe Stem Cell Bioengineering Co., Ltd. It is a legal attestation or certification by shareholders rather than a financial report or announcement of financial results. The document is short (1037 characters) and consists mainly of signatures and legal commitments. It does not contain financial data, management discussion, or report content. Therefore, it fits best under Regulatory Filings (RNS) as a legal or compliance-related filing rather than a financial report or announcement.
2014-02-23 Chinese
独立董事关于公司发行股份及支付现金购买资产并募集配套资金暨关联交易的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding a company's issuance of shares and payment of cash to purchase assets and raise supporting funds, which is described as a major asset restructuring and related party transaction. The document discusses the fairness, legality, and approval process of the transaction, including board and shareholder approvals and regulatory compliance. It is not a full financial report but an independent directors' opinion on a specific transaction and related governance matters. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure related to a transaction and independent directors' opinion, not a full report or announcement of voting results.
2014-02-23 Chinese
重大资产重组延期复牌公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the extension of a trading suspension due to a major asset restructuring. It mentions the postponement of the resumption of trading and the scheduling of board meetings to review the restructuring plan. There is no financial data, no detailed report, no audit information, no voting results, or any other detailed filings. The document is an announcement about the status of a capital restructuring process and trading suspension, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or a certification. Therefore, the best classification is CAP with high confidence.
2014-02-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.